News &

Press

venBio news

“venBio Raises $550 Million Venture Capital Fund Focused on Life Sciences.”

“venBio Closes $394 Million Life Sciences Venture Capital Fund.”

Portfolio news

Akero Announces Strongly Positive Histological Data Across All Efruxifermin Dose Groups in 16-Week Phase 2a BALANCED Study in NASH Patients

Jun 30, 2020

Artiva Biotherapeutics Launches with $78 Million Series A Financing to Advance NK Cell Therapies to Treat Cancer

Jun 26, 2020

Checkmate Pharmaceuticals Secures $85 Million in Series C Financing

Jun 10, 2020

NFlection Therapeutics Launches with $20M Series A Funding to Advance Lead Program in Neurofibromatosis

Jun 9, 2020

Roche makes a platform play, betting $190M in cash on Arrakis’ long-haul plans to drug RNA

Apr 8, 2020

All AKR-001 Dose Groups Met Week 12 Efficacy Endpoints in NASH Phase 2a BALANCED Study

Mar 31, 2020

ALX Oncology Announces Closing of $105 Million Series C Financing

Feb 12, 2020

San Francisco office

1700 Owens Street, Suite 595
San Francisco, CA 94158

Seattle office

1200 Westlake Ave N, Suite 900
Seattle, WA 98109

© 2023 venBio. All Rights Reserved.